GNFTF - Genfit And Elafibranor In NASH Fibrosis: The FDA Guidelines For Conditional Approval
The Update On Genfit Pharmaceuticals
Genfit (OTCPK:GNFTF) is a clinical stage small-cap ($653M) biopharmaceutical company that is clinically developing innovative therapeutics and biomarkers for the prevention and treatment of cardiometabolic diseases including NASH. Its lead investigative drug candidate, elafibranor, is currently in Phase 3 clinical trial for NASH fibrosis as well as Phase 2 clinical trials for pediatric NASH and PBC.
Elafibranor is an oral once-daily treatment and a first-in-class novel dual PPAR-α/δ agonist. Elafibranor is a member of the “fab four” Phase 3 anti-NASH drug candidates (selonsertib, obeticholic acid, elafibranor and cenicriviroc)